First-Line Cyramza in NSCLC Gets Split Decision From FDA Panel

]]>(MedPage Today) -- SILVER SPRING, Md.--An FDA advisory panel was split on Wednesday over whether to recommend approval of ramucirumab (Cyramza) as an add-on to first-line treatment for patients with metastatic EGFR-mutant non-small cell lung...